Stockholders' Equity (Details 2) (USD $)	0 Months Ended	9 Months Ended						0 Months Ended		0 Months Ended		0 Months Ended
	Feb. 06, 2014	Sep. 30, 2014	Feb. 06, 2014	Dec. 31, 2013	Feb. 18, 2014 Weighted average	Dec. 31, 2013 Weighted average	Feb. 18, 2014 ContraVir Subsidiary Spin-off	Feb. 04, 2014 February 4, 2014 Private Placement ContraVir Subsidiary	Feb. 04, 2014 February 4, 2014 Private Placement ContraVir Subsidiary	Feb. 04, 2014 February 4, 2014 Private Placement ContraVir Subsidiary Warrants	Feb. 04, 2014 February 4, 2014 Private Placement ContraVir Subsidiary Warrants	Feb. 18, 2014 ContraVir Subsidiary	Feb. 18, 2014 ContraVir Subsidiary Spin-off	Mar. 27, 2014 ContraVir Subsidiary Loan Agreement	Jan. 09, 2014 ContraVir Subsidiary Loan Agreement	Oct. 18, 2013 ContraVir Subsidiary Loan Agreement	Aug. 29, 2013 ContraVir Subsidiary Loan Agreement	Jun. 05, 2013 ContraVir Subsidiary Loan Agreement	Nov. 18, 2013 ContraVir Subsidiary Loan Agreement	Jun. 05, 2013 ContraVir Subsidiary Loan Agreement
Stockholders' equity
Gross proceeds		$ 3,224,000						$ 3,200,000
Expenses related to private placement								15,000
Number of units sold (in shares)								9,485,294
Number of shares of common stock per unit								1
Number of warrants per unit (in shares)								1
Number of common shares that can be acquired upon exercise of each warrant									0.5
Purchase price (in dollars per unit)								$ 0.34
Expiration period of warrant										6 years
Exercise price (in dollars per share)					$ 5.359	$ 5.37					$ 0.37
Derivative liabilities related to Warrants		130,000		1,534,000							880,000
Shares of subsidiary distributed for each share of the entity's shares outstanding												0.0986
Assets
Cash							3,230,000
Prepaid expense							6,000
Total assets							3,236,000
Liabilities
Accounts payable and other liabilities							(107,000)
Note Payable to Synergy							(455,000)
Due to Synergy							(54,000)
Derivative financial instruments, at estimated fair value-warrants							(880,000)
Total Liabilities							(1,496,000)
Net assets							1,740,000
Decrease in non-controlling interest		1,622,000											1,600,000
Decrease in exercise price (in dollars per share)	$ 0.011
Non-public warrants outstanding (in shares)		5,647,203	5,647,203								4,700,000
Maximum amount the entity agreed to lend																			1,000,000	500,000
Amount of advance to subsidiary															100,000	150,000	100,000	100,000
Interest rate (as a percent)																				6.00%
Repayment of advance by ContraVir														$ 461,236